» Articles » PMID: 22457286

Opportunities and Challenges for Cost-efficient Implementation of New Point-of-care Diagnostics for HIV and Tuberculosis

Abstract

Stakeholders agree that supporting high-quality diagnostics is essential if we are to continue to make strides in the fight against human immunodeficiency virus (HIV) and tuberculosis. Despite the need to strengthen existing laboratory infrastructure, which includes expanding and developing new laboratories, there are clear diagnostic needs where conventional laboratory support is insufficient. Regarding HIV, rapid point-of-care (POC) testing for initial HIV diagnosis has been successful, but several needs remain. For tuberculosis, several new diagnostic tests have recently been endorsed by the World Health Organization, but a POC test remains elusive. Human immunodeficiency virus and tuberculosis are coendemic in many high prevalence locations, making parallel diagnosis of these conditions an important consideration. Despite its clear advantages, POC testing has important limitations, and laboratory-based testing will continue to be an important component of future diagnostic networks. Ideally, a strategic deployment plan should be used to define where and how POC technologies can be most efficiently and cost effectively integrated into diagnostic algorithms and existing test networks prior to widespread scale-up. In this fashion, the global community can best harness the tremendous capacity of novel diagnostics in fighting these 2 scourges.

Citing Articles

Assessing the impact of HIV self-testing on diagnosis rates in vulnerable groups in belo horizonte, Brazil: A cross-sectional analysis.

Innecco Areas J, Braganca Costa E Moreira G, Picchioni Baeta G, Novaes J, Castro de Sousa Pires L, Dos Santos L Public Health Pract (Oxf). 2025; 9():100567.

PMID: 39831083 PMC: 11742301. DOI: 10.1016/j.puhip.2024.100567.


Strengthening laboratory systems for ensuring accurate diagnoses in mother-to-child transmission (MTCT) prevention programs in Uganda: a narrative review.

Obeagu E, Obeagu G Ann Med Surg (Lond). 2024; 86(9):5256-5265.

PMID: 39239033 PMC: 11374211. DOI: 10.1097/MS9.0000000000002154.


Impact of simplified HCV diagnostic strategies on the HCV epidemic among men who have sex with men in the era of HIV oral pre-exposure prophylaxis in Taiwan: a modelling study.

Wu H, Shih S, Applegate T, Kwon J, Cunningham E, Grebely J J Int AIDS Soc. 2024; 27(5):e26251.

PMID: 38695100 PMC: 11063777. DOI: 10.1002/jia2.26251.


Understanding health systems challenges in providing Advanced HIV Disease (AHD) care in a hub and spoke model: a qualitative analysis to improve AHD care program in Malawi.

Maphosa T, Denoeud-Ndam L, Kapanda L, Khatib S, Chilikutali L, Matiya E BMC Health Serv Res. 2024; 24(1):244.

PMID: 38408975 PMC: 10897989. DOI: 10.1186/s12913-024-10700-1.


Point-of-Care and Rapid Tests for the Etiological Diagnosis of Respiratory Tract Infections in Children: A Systematic Review and Meta-Analysis.

Brigadoi G, Gastaldi A, Moi M, Barbieri E, Rossin S, Biffi A Antibiotics (Basel). 2022; 11(9).

PMID: 36139971 PMC: 9494981. DOI: 10.3390/antibiotics11091192.


References
1.
Chohan B, Emery S, Wamalwa D, John-Stewart G, Majiwa M, Ngayo M . Evaluation of a single round polymerase chain reaction assay using dried blood spots for diagnosis of HIV-1 infection in infants in an African setting. BMC Pediatr. 2011; 11:18. PMC: 3050718. DOI: 10.1186/1471-2431-11-18. View

2.
Smith S, Kurbatova E, Cavanaugh J, Cegielski J . Global isoniazid resistance patterns in rifampin-resistant and rifampin-susceptible tuberculosis. Int J Tuberc Lung Dis. 2011; 16(2):203-5. PMC: 4593497. DOI: 10.5588/ijtld.11.0445. View

3.
Mtapuri-Zinyowera S, Chideme M, Mangwanya D, Mugurungi O, Gudukeya S, Hatzold K . Evaluation of the PIMA point-of-care CD4 analyzer in VCT clinics in Zimbabwe. J Acquir Immune Defic Syndr. 2010; 55(1):1-7. DOI: 10.1097/QAI.0b013e3181e93071. View

4.
Creek T, Sherman G, Nkengasong J, Lu L, Finkbeiner T, Fowler M . Infant human immunodeficiency virus diagnosis in resource-limited settings: issues, technologies, and country experiences. Am J Obstet Gynecol. 2007; 197(3 Suppl):S64-71. DOI: 10.1016/j.ajog.2007.03.002. View

5.
Reynolds S, Muwonga J . OraQuick ADVANCE Rapid HIV-1/2 antibody test. Expert Rev Mol Diagn. 2004; 4(5):587-91. DOI: 10.1586/14737159.4.5.587. View